Biomedical subjects

D Reisman

Publications and source records attributed to D Reisman.

35 records · Page 2Linked to original sources

PubMed1995

Glucocorticoid regulation of cyclin D3 gene transcription and mRNA stability in lymphoid cells.

Glucocorticoids cause G0/G1 arrest of lymphoid cells. This is due, at least in part, to a decrease in the abundance of the G1 progression factor, cyclin D3. The mRNA encoding cyclin D3 (CcnD3 mRNA) is rapidly down-regulated when dexamethasone is added to P1798 murine T lymphoma cells. Fifty percent maximum inhibition is observed within about 2 h. Maximum inhibition of 75-85% obtains within 4-5 h. Cyclin D3 protein has a half-life of about 0.5 h in P1798 cells. Consequently, the abundance of cyclin D3 protein decreases in parallel with the abundance of CcnD3 mRNA. The effects of glucocorticoids are reversible. CcnD3 mRNA returns to near control levels within 2-3 h after removal of dexamethasone. Cyclin D3 protein recovers somewhat more slowly. The data indicate that glucocorticoids regulate the abundance of cyclin D3 mRNA. There is no significant decrease in nuclear run-on transcription of CcnD3 within 6 h after addition of glucocorticoids, although transcription is inhibited more than 80% after 24 h in the presence of dexamethasone. CcnD3 mRNA is very stable in mid-log phase P1798 cells, with a half-life of more than 8 h. The half-life of CcnD3 mRNA in glucocorticoid-treated cells is less than 1 h. Actinomycin D blocks the effects of glucocorticoids, suggesting that dexamethasone induces a substance that increases the turnover rate of CcnD3 mRNA. Regulation of CcnD3 mRNA abundance and of CcnD3 transcription has been studied in cells arrested at the G1/S interface by thymidine blockade. Glucocorticoids down-regulate CcnD3 mRNA in the absence of cell cycle progression. This observation indicates that glucocorticoid inhibition of cyclin D3 expression is not a secondary consequence of cell cycle arrest. However, glucocorticoids have no significant effect on transcription of CcnD3 in G1/S phase-arrested cells. Inhibition of transcription of CcnD3 is a delayed response and probably reflects withdrawal into a G0 state, rather than any proximal consequence of glucocorticoid action. Destabilization of CcnD3 mRNA appears to be a direct effect of glucocorticoids, independent of cell cycle progression, and mediated by a glucocorticoid-induced protein(s) that accelerates the degradation of CcnD3 mRNA.

Animals↗

PubMed1995

Glucocorticoid regulation of G1 cyclin-dependent kinase genes in lymphoid cells.

These experiments were undertaken to study cell cycle-dependent regulation of expression of genes encoding cyclin-dependent kinases (Cdks). P1798 T-lymphoma cells were studied as a model system, since these cells undergo reversible G0 arrest within 24 h after addition of 0.1 microM dexamethasone to mid log phase cultures. G0 arrest is associated with inhibition of expression of several Cdks. The mRNAs encoding Cdk1 and Cdk4 decreased by 80-90% within 24 h. Fifty % inhibition of Cdk4 mRNA occurred within about 4 h, and 50% inhibition of Cdk1 mRNA was observed within 12-14 h. There was a slight decrease (< 50%) in the abundance of the mRNAs encoding Cdk2 and Cdk5. Cdk6 mRNA did not decrease in glucocorticoid-treated cells. Cdk1 and Cdk2 protein levels were reduced by no more than 50-70% within 24 h after the addition of dexamethasone, and the amounts of Cdk5 and Cdk6 protein did not change. However, the amount of Cdk4 protein decreased by > 90% under these circumstances. P1798 cells enter S phase in a synchronous fashion within 16-20 h after removal of dexamethasone. Cdk1, Cdk2, and Cdk5 mRNAs and proteins increased at or after the time that cells began to enter S phase. The mRNA encoding Cdk4 increased much more rapidly after removal of glucocorticoids, and a 5-fold increase in Cdk4 mRNA abundance was observed within 8 h after removal of the steroid. A corresponding increase in Cdk4 protein was observed, indicating that inhibition of Cdk4 expression is more proximal to the glucocorticoid-induced blockade in G1 progression.(ABSTRACT TRUNCATED AT 250 WORDS)

Cyclin-Dependent Kinase 4↗

PubMed1994

Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Elevated levels of mutant forms of the p53 tumor suppressor are a hallmark of many transformed cells. Multiple mechanisms such as increased stability of the protein and increased transcription of the gene can account for elevated p53 expression. Recent findings indicate that c-Myc/Max heterodimers can bind to an essential CA(C/T)GTG-containing site in the p53 promoter and elevate its expression. We have addressed the possibility that elevated mutant p53 expression is due to deregulated c-Myc expression. Here we demonstrate that the human p53 promoter is transactivated by high c-Myc expression and repressed by high Max expression. In examining the relative levels of c-Myc and p53 in human Burkitt's lymphomas and other B-lymphoid lines, we found that there is a correlation between the levels of c-Myc protein and p53 mRNA expression. In particular, cells that express very low levels of c-Myc protein also express low levels of p53 mRNA, while cells that express high levels of c-Myc tend to express high levels of p53 mRNA. To determine whether the p53 gene can be a target for c-Myc in vivo, we assayed the effects of antisense c-myc RNA on the levels of endogenous p53 mRNA. The results indicate that the presence of antisense c-myc RNA leads to a reduction in the levels of c-Myc protein, p53 mRNA, and expression from the p53 promoter. Taken together, our findings support a direct role for c-Myc in elevating expression of the mutant p53 gene in some tumors.

Animals↗

PubMed1993

The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene.

Expression of the wild-type p53 tumor suppressor gene has been found to play an important role in the regulation of cellular proliferation and differentiation. In addition, in many transformed cells and primary tumors, the gene has undergone allelic deletions and mutant forms of the p53 gene are expressed at elevated levels. In defining transcriptional regulatory regions of the p53 gene, we have previously shown that both the human and murine p53 promoters contain a conserved consensus recognition sequence for the basic-helix-loop-helix (bHLH) containing family of DNA-binding proteins. In the murine p53 promoter this element is required for full promoter activity and contains the sequence CACGTG, a sequence identical to the recognition site for the bHLH containing transcription factors c-Myc, USF and TFE3. Here we examine the ability of one of these factors, USF, to bind to the p53 promoter. By assaying the binding activity of in vitro translated USF as well as factors present in nuclear extracts, we conclude that the transcription factor USF binds in a site-specific manner to a CACGTG motif within the murine p53 promoter and represents the major DNA-binding activity observed in nuclear extracts. Elevated levels of USF, generated upon transfection of a vector expressing USF, lead to enhanced activity of the p53 promoter. These findings indicate that USF may play a central role in regulating p53 expression.

3T3 Cells↗

PubMed1993

c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif.

c-Myc and wild-type p53 have been shown to play important roles in the regulation of cellular proliferation and oncogenic transformation. We have previously shown that the p53 promoter contains a conserved consensus recognition sequence for the basic-helix-loop-helix-containing proteins, identical to the specific binding site for c-Myc/Max heterodimers. Here, we demonstrate that this element, which is required for full promoter activity, is bound by in vitro translated c-Myc/Max heterodimers. Furthermore, we found that in cotransfection assays, c-Myc trans-activates the p53 promoter as well as a hybrid herpes simplex virus-thymidine kinase promoter containing multiple copies of a synthetic p53-derived c-Myc binding site. The p53 promoter deleted of the basic-helix-loop-helix consensus recognition sequence is not trans-activated by c-Myc, thus suggesting that c-Myc trans-activates the p53 promoter through the basic-helix-loop-helix recognition motif. These findings raise the possibility that the p53 gene may be a potential target for trans-activation by c-Myc in vivo.

Animals↗

PubMed1991

Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif.

Expression of the p53 gene plays an important role in the regulation of cellular proliferation and malignant transformation. Overexpression of mutant forms of p53 is in fact a common feature of many transformed cells. Studies dealing with the transcriptional regulatory regions of the p53 gene indicate that, unlike most promoters transcribed by RNA polymerase II, the p53 promoter contains no TATA-like sequence upstream of the transcription start site. Here we demonstrate that the murine p53 promoter contains a cis-acting element that maps downstream to the transcription initiation site. The integrity of this element is required for high-level expression from the promoter in transformed cells. By DNase I protection and mobility-shift analysis, we show that a nuclear factor binds to this downstream element through the consensus recognition sequence for the helix-loop-helix (HLH)-containing proteins of the myc/MyoD family of transcriptional regulators. We propose that the activity of one or more members of this family of transcription factors is an important determinant in the expression of p53 and that at least one level of p53 overexpression in transformed cells may thus be due to aberrant expression of the relevant factor(s). Furthermore, the possibility that the regulation of expression of p53 occurs, in part, by means of a potential HLH-containing factor provides a possible mechanism for the suppression of proliferation by the MyoD family of transcriptional regulators.

Animals↗

PubMed1990

Nuclear factor-1 (NF-1) binds to multiple sites within the transcriptional enhancer of Moloney murine leukemia virus.

The transcriptional enhancer of the Moloney Murine Leukemia virus (Mo-MuLV) is comprised of a 75-bp direct repeat, each of which contains multiple binding sites for transcription factors. The occupancy of these sites determines the tissue specificity of expression and disease tropism of the virus. The identification of proteins that bind to this enhancer is therefore required in order to understand the molecular basis of this viral-host interaction. Analysis of the nucleic acid sequence of the Mo-MuLV has identified 4 potential binding sites for the transcription factor NF-1. Evidence is presented using DNAase I protection analysis that NF-1 binds to these 4 sites within the enhancer. The potential role of NF-1 binding in tissue specific expression of Mo-MuLV is discussed.

Base Sequence↗

PubMed1989

Induced expression from the Moloney murine leukemia virus long terminal repeat during differentiation of human myeloid cells is mediated through its transcriptional enhancer.

Transcription from the Moloney murine leukemia virus (Mo-MuLV) long terminal repeat (LTR) is inhibited in murine stem cells and induced during maturation of these cells. We have investigated whether alterations in the activity of this viral regulatory element also occur during differentiation of human myeloid leukemia cells. The Mo-MuLV LTR and the simian virus 40 (SV40) early promoter were introduced into HL-60 promyelocytes on Epstein-Barr virus-derived chloramphenicol acetyltransferase expression vectors. When these cells were induced to terminally differentiate, transcription from the Mo-MuLV LTR was induced approximately 10-fold. Expression from the SV40 promoter remained constant during differentiation of these cells. Replacing the SV40 transcriptional enhancer with the Mo-MuLV LTR transcriptional enhancer rendered the SV40 promoter inducible during differentiation. We conclude that sequences within the transcriptional enhancer of the Mo-MuLV LTR contain cis-acting elements responsible for induction of gene expression during differentiation of human myeloid cells.

Cell Differentiation↗

PubMed1989

Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells.

p53 is overexpressed in many transformed cells and expression of the gene is known to alter during terminal differentiation of cells in culture. Through analysis of recombinant vectors expressing the chloramphenicol acetyl transferase (CAT) gene we found that two promoters map to the 5'-portion of the human p53 oncogene. One promoter, p53p1, maps upstream of the non-coding first exon and the second, p53p2, maps within the first intron. By primer extension analysis of cellular RNA from a number of human cell lines, we found that p53p2 is a functional promoter in vivo. In order to test whether differential regulation of these promoters may be correlated with the control of expression of the p53 gene during differentiation, we have measured the activity of the two promoters by their ability to direct expression of the CAT gene during terminal differentiation of the human promyelocytic leukemia cell line HL-60. HL-60 cells stably harboring Epstein-Barr virus-derived recombinant plasmids that express the CAT gene from either p53p1 or p53p2 were induced to undergo terminal differentiation by a variety of chemical inducers to either granulocytes or monocytes and expression of the CAT gene was measured. The results indicate that while expression of p53p1 remained constant, expression from p53p2 was induced 5- to 10-fold during differentiation of these cells to either granulocytes or monocytes. Similarly, the endogenous p53p2 was found to be induced in HL-60 cells undergoing differentiation. Although the product of the p53p2 initiated transcript has not yet been characterized these results indicate that altered regulation of these two promoters may be important in modulating the expression of mRNA from this gene during terminal differentiation.

Cell Cycle↗

PubMed1988

Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1.

To gain insight into how transcription of the human p53 oncogene is controlled, we characterized the regulatory regions of the gene. A 3.8-kilobase-pair (kbp) EcoRI restriction fragment encompassing the 5' end of the human p53 gene, as well as subfragments generated by restriction digests, was cloned upstream of the Escherichia coli chloramphenicol acetyltransferase (CAT) gene and CAT activity was assayed in extracts of transfected cells. Two types of CAT vectors were used: Epstein-Barr virus oriP-derived constructs that were stably introduced into the human cell lines K562, Raji, and HL-60, and pSV0-CAT-derived constructs that were transiently introduced into the monkey cell line COS. By this approach we have identified two promoters for the human p53 gene. One promoter, p53P1, is located 100-250 bp upstream of the 218-bp noncoding first exon; a second, stronger promoter, p53P2, maps within the first intron. CAT activity and expression of CAT RNA indicate that p53P2 functions up to 50-fold more efficiently than p53P1. We conclude that the expression of the human p53 gene may be controlled by two promoters and that differential regulation of these promoters may play an important role in the altered expression of the gene in both normal and transformed cells.

Acetyltransferases↗

PubMed1987

Inhibition of cell growth mediated by plasmids encoding p53 anti-sense.

p53 is an oncogene product which has been shown to be directly involved in malignant transformation. Furthermore, it has been proposed that this protein plays an essential role in the control of cell proliferation. In the present study, we investigated the involvement of p53 in growth regulation of cells by employing anti-sense RNA methodology to inhibit p53 expression. Transfection with p53-specific constructs spanning the entire mRNA molecule or the 5' region of the gene led to reduced p53 protein synthesis. Clones derived from such transfected cells exhibited a slower rate of DNA synthesis, as assayed by incorporation of [3H]thymidine. In most cases, transfection of plasmids encoding anti-sense RNA eventually brought about the complete cessation of cell proliferation. No such effects were observed in L12 cells, which do not synthesize p53 and therefore do not depend on p53 expression for their growth, thus excluding the possibility of a non-specific toxic effect exerted by the anti-sense p53 RNA. These findings support the notion that p53 is essential for continuous cell proliferation.

Animals↗

PubMed1986

trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1.

Two regions of the Epstein-Barr virus (EBV) genome together make up an element, oriP, which acts in cis to support plasmid replication in cells that express the EBV nuclear antigen 1 (EBNA-1). The two components of oriP are a region containing a 65-base-pair (bp) dyad symmetry and a region containing 20 copies of a 30-bp direct repeat. Here we show that the 30-bp family of repeats of oriP can function as a transcriptional enhancer that is activated in trans by the EBNA-1 gene product. In either EBV-genome-positive cells or in cells that express EBNA-1, the 30-bp family of repeats, when positioned in either orientation upstream or downstream, enhances expression of the chloramphenicol acetyltransferase (CAT) gene expressed from either the simian virus 40 early promoter or the herpes simplex virus type 1 thymidine kinase promoter. The extent of transcriptional enhancement varies with the promoter and cell type. This enhanced CAT expression reflects an increased level of CAT mRNA and does not result from amplification of the plasmids expressing CAT. In addition, plasmids carrying the gene for resistance to hygromycin B and the 30-bp family of repeats yielded 10 to 100 times more hygromycin B-resistant colonies than the vector lacking the 30-bp family of repeats in both EBV-genome-positive cells and cells that express EBNA-1. EBNA-1 is known to bind to sequences within the 30-bp family of repeats (D. R. Rawlins, G. Milman, S. D. Hayward, and G. S. Hayward, Cell 42:859-868, 1985), and these trans- and cis-acting elements together have at least two functional roles: (i) they are required for DNA replication dependent upon oriP, and (ii) they can enhance expression of genes linked to the 30-bp family of repeats of oriP.

Acetyltransferases↗

PubMed1985

A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components.

A genetic element of Epstein-Barr virus, oriP, when present on recombinant plasmids allows those plasmids to replicate and to be maintained in cells that express the Epstein-Barr virus-encoded nuclear antigen EBNA-1. Here we define the DNA sequences required for oriP activity. Two noncontiguous regions of oriP are required in cis for activity. One consists of approximately 20 tandem, imperfect copies of a 30-base-pair (bp) sequence. The other required region, approximately 1,000 bp away, is at most 114 bp in length and contains a 65-bp region of dyad symmetry. When present together on a plasmid, these two components supported plasmid replication even when the distance between them was varied or their relative orientation was altered, or both. When present alone on a plasmid that expresses a selectable marker, the family of 30-bp repeats efficiently conferred a transient drug-resistant phenotype in human 143 cells that is dependent on the presence of EBNA-1. This result leads us to suggest that EBNA-1 interacts with the 30-bp repeated sequence to activate oriP. To test whether the 30-bp repeats might cause the increased transient expression of drug resistance by enhancing transcription, the family of 30-bp repeats was tested for the ability to activate the simian virus 40 early promoter present in plasmid pA10CAT2 (Laimins, et al., Proc. Natl. Acad. Sci. U.S.A. 79:6453-6457). In this assay, the 30-bp repeats could activate the simian virus 40 early promoter in Raji cells, an EBNA-positive Burkitt's lymphoma cell line, but not detectably an EBNA-positive 143 cells in which oriP also functions.

Acetyltransferases↗

PubMed1984

An EBNA-negative, EBV-genome-positive human lymphoblast cell line in which superinfecting EBV DNA is not maintained.

A human B-lymphoid cell line, designated TG8, which does not express detectable levels of the EBV (Epstein-Barr virus)-associated nuclear antigen (EBNA), yet carries an average of one to two plasmid copies of the P3HR-1 EBV genome has been identified. TG8 can be superinfected by B95-8 EBV, resulting in up to 60-70% of the population becoming EBNA-positive and 20-30% of the incoming EBV genomes becoming circular by 48 hr postinfection. Neither EBNA expression nor the superinfecting viral DNA is maintained in the population. It is concluded that (1) superinfection of this EBV-genome-positive lymphoblast cell line leads to detectable EBNA expression and circularization of the incoming viral genome and (2) the incoming viral genome and detectable EBNA expression are selectively lost, whereas the endogenous viral plasmid DNA is maintained.

Animals↗

PubMed1984

A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells.

The Epstein-Barr viral (EBV) genome of approximately equal to 170 kilobase pairs (kbp) is maintained as a plasmid in human B lymphoblasts transformed by the virus. We have identified a cis-acting element within 1.8 kbp of the viral genome that allows recombinant plasmids carrying it to be selected at high frequency and maintained as plasmids in cells latently infected by EBV. This functional element(s) requires a segment of DNA at least 800 bp and at most 1800 bp long, which contains a family of 30-bp tandem repeats at one end. Since this region confers efficient stable replication only to plasmids transfected into cells containing EBV genomes, its function probably requires trans-acting products encoded elsewhere in the viral genome.

DNA Replication↗

PubMed1981

Is selective therapy of recurrent nephrolithiasis possible?

We evaluated, in 128 patients with recurrent nephrolithiasis, the efficacy of special treatment programs for some of the common causes of nephrolithiasis, chosen on the basis of their ability to correct underlying physicochemical and physiologic derangements. Therapy included sodium cellulose phosphate for 18 patients with absorptive hypercalciuria, thiazide diuretics for 27 patients with absorptive hypercalciuria and for 10 with renal hypercalciuria, orthophosphate for eight patients with hypophosphatemic absorptive hypercalciuria, allopurinol for 21 patients with hyperuricosuric calcium oxalate nephrolithiasis, thiazide and allopurinol for 26 patients with absorptive hypercalciuria with hyperuricosuria, and high fluid intake and/or low calcium diet for 22 patients with normocalciuric nephrolithiasis. Patients in all seven groups had a significant reduction in stone formation during 1.70 to 3.37 years of treatment, as compared with the pretreatment period of three years. Remission was found in 70 to 91 percent of patients and reduced stone formation rate was encountered in 88 to 100 percent. Each treatment program produced a significant decline in stone formation rate from 1.90 to 2.28 stones per year to 0.09 to 0.55 stones per year. The actual number of stones formed during treatment was significantly lower than the number predicted from the pretreatment frequency of stone formation (less than 26 percent). The results provide evidence supporting a selective approach to therapy of nephrolithiasis.

Allopurinol↗

PubMed1981

Cloning overlapping DNA fragments from the B95-8 strain of Epstein-Barr virus reveals a site of homology to the internal repetition.

Overlapping, sheared DNA fragments from the B95-8 strain of Epstein-Barr virus were cloned in Charon 4A. Eleven recombinant phages plus one recombinant plasmid contained all of the sequences found in B95-8 virion DNA. Analysis of recombinant DNA molecules revealed a previously undetected site of homology to the internal repetition found in Epstein-Barr virus DNA. This site was adjacent to or at a site which was unstable when the recombinant DNA was propagated as phage DNA in procaryotic hosts.

Cloning, Molecular↗